American Journal of Kidney Diseases
Volume 50, Issue 6 , Pages 1001-1008 , December 2007

Neuropeptide Y and Markers of Osteoblast Activity in Dialysis Patients: A Cross-Sectional Study

Received 17 April 2007 ,Accepted 6 September 2007.

References 

  1. Sherrard DJ, Hercz G, Pei Y, et al. The spectrum of bone disease in end-stage renal failure—An evolving disorder. Kidney Int. 1993;43:436–442
  2. Malluche HH, Faugere MC. Risk of adynamic bone disease in dialyzed patients. Kidney Int Suppl. 1992;42:S62–S67
  3. Navarro JF, Mora C, Jimenez A, Torres A, Macia M, Garcia J. Relationship between serum magnesium and parathyroid hormone levels in hemodialysis patients. Am J Kidney Dis. 1999;34:43–48
  4. Brancaccio D, Zoccali C. Continuous challenge of cardiovascular and bone and bone disease in uremic patients: Clinical consequences of hyperphosphatemia and advanced therapeutic approach. J Nephrol. 2006;19:12–20
  5. Hernandez JD, Wesseling K, Salusky IB. Role of parathyroid hormone and therapy with active vitamin D sterols in renal osteodistrophy. Semin Dial. 2005;18:290–295
  6. Jehle PM, Ostertag A, Schulten K, Schulz W, Jehle DR, Stracke S. Insulin-like growth factor system components in hyperparathyroidism and renal osteodystrophy. Kidney Int. 2000;57:423–436
  7. Panuccio V, Mallamaci F, Tripepi G, et al. Low parathyroid hormone and pentosidine in hemodialysis patients. Am J Kidney Dis. 2002;40:810–815
  8. Caro JF, Besarab A, Burke JF, Glennon JA. A possible role for propranolol in the treatment of renal osteodystrophy. Lancet. 1978;2:451–454
  9. Hruska KA, Teitelbaum SL. Renal osteodystrophy. N Engl J Med. 1995;20:166–174
  10. Ducy P, Amling M, Takeda S, et al. Leptin inhibits bone formation through a hypothalamic relay: A central control of bone mass. Cell. 2000;100:197–207
  11. Baldock PA, Sainsbury A, Couzens M, et al. Hypothalamic Y2 receptors regulate bone formation. J Clin Invest. 2002;109:915–921
  12. Baldock PA, Allison S, McDonald MM, et al. Hypothalamic regulation of cortical bone mass: Opposing activity of Y2 receptor and leptin pathways. J Bone Miner Res. 2006;21:1600–1607
  13. Stridsberg M, Lundqvist G. Radioimmunoassay of neuropeptide Y (NPY) in biological fluids (Circulating NPY levels depend on renal function). Clin Chim Acta. 1989;185:61–71
  14. Coen G, Ballanti P, Bonucci E, et al. Bone markers in the diagnosis of low turnover osteodystrophy in haemodialysis patients. Nephrol Dial Transplant. 1998;13:2294–2302
  15. In: Practical Statistics for Medical Research. ed 1. London, UK: Chapman & Hall; 1991;p. 303
  16. Baldock PA, Sainsbury A, Couzens M, et al. Neuropeptide Y, tyrosine hydrolase- and vasoactive intestinal polypeptide-immunoreactive nerves in bone and surrounding tissues. J Auton Nerv Syst. 1988;25:119–125
  17. Kalra SP, Kalra PS. NPY—Endearing journey in search of neurochemical on/off switch for appetite, sex and reproduction. Peptides. 2001;22:309–315
  18. Baldock PA, Sainsbury A, Allison S, et al. Hypothalamic control of bone formation: Distinct actions of leptin and y2 receptor pathways. J Bone Miner Res. 2005;20:1851–1857

 Originally published online as doi:10.1053/j.ajkd.2007.09.001 on October 30, 2007.

PII: S0272-6386(07)01238-3

doi: 10.1053/j.ajkd.2007.09.001

American Journal of Kidney Diseases
Volume 50, Issue 6 , Pages 1001-1008 , December 2007

Article Tools

* Image Usage & Resolution